Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sunshine Biopharma, Inc. (SBFM)
USD2.11
-0.07 (-3.21%)
CA NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
Address
6500 Trans-Canada Highway H9R 0A5
Pointe-Claire, QC, CA
Pointe-Claire, QC, CA
CEO
Steve N. Slilaty
Website
sunshinebiopharma.com
IPO
2022-02-15
CIK 1402328 ISIN US8677818093
Also trades on
NASDAQ Capital Market · SBFM (USD)
NASDAQ Capital Market · SBFMW (USD)
Description
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Date | Filing |
|---|---|---|
| CANADA | 2014-02-03 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.11
-0.07 (-3.21%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.31
Float Shares
4.90M
Free Float %
97.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -19.84% | -42.90% | -73.59% | -78.83% | -82.48% | -79.34% | -82.11% | -99.98% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
2.11
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.30
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+4.1% Q1'26: -9.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+80.3% ★ Q1'26: +43.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-16.0% Q1'26: -25.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-12.3% Q1'26: -17.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-30.4% Q1'26: -36.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+492.4% Q1'26: +81.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.20× Q1'26: -0.14× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
24.09M
est: 21.03M (+14.5%)
|
34.87M
est: 37.80M (-7.7%)
|
36.31M
est: 37.73M (-3.8%)
|
35.40M
35.40M – 35.40M
-6.2% YoY
|
45.00M
45.00M – 45.00M
+27.1% YoY
|
| EBITDA |
-3.82M
est: -13.91M (+72.5%)
|
-5.14M
est: -18.30M (+71.9%)
|
-4.15M
est: -18.26M (+77.3%)
|
-17.14M
-17.14M – -17.14M
+6.2% YoY
|
-21.78M
-21.78M – -21.78M
-27.1% YoY
|
| EBIT |
-3.97M
est: -13.96M (+71.5%)
|
-5.36M
est: -18.46M (+71.0%)
|
-4.48M
est: -18.43M (+75.7%)
|
-17.29M
-17.29M – -17.29M
+6.2% YoY
|
-21.98M
-21.98M – -21.98M
-27.1% YoY
|
| Net Income |
-4.51M
est: -224.56M (+98.0%)
|
-5.13M
est: -17.13M (+70.0%)
|
-5.98M
est: -4.20M (-42.3%)
|
-2.62M
-2.62M – -2.62M
+37.6% YoY
|
83.1K
83.1K – 83.1K
+103.2% YoY
|
| SGA |
10.83M
est: 79.48M (-86.4%)
|
14.94M
est: 88.96M (-83.2%)
|
19.63M
est: 88.79M (-77.9%)
|
83.31M
83.31M – 83.31M
-6.2% YoY
|
105.91M
105.91M – 105.91M
+27.1% YoY
|
| EPS |
-351.36
est: -320.00 (-9.8%)
|
-7.32
est: -4.12 (-77.7%)
|
-1.44
est: -1.01 (-42.6%)
|
-0.63
-0.63 – -0.63
+37.6% YoY
|
0.02
0.02 – 0.02
+103.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-20 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-19 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-18 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-15 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-5.55M
OE per share TTM
-8.89
Owner's Yield
-449.49%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
5.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
7
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | L1 Capital Global Opportunities Master Fund, Ltd. | 5.29M | 5.30% | 5.29M | — | — | — | FI | Cayman Islands | 2024-02-23 | ↗ |
| 2 | Applicable | 3.70M | 16.40% | 3.70M | — | 3.70M | — | IN | Canada | 2022-11-02 | ↗ |
| 3 | Altium Capital Management, LP | 2.86M | 9.99% | — | 2.86M | — | 2.86M | IA, PN | Delaware, United States of America | 2024-02-21 | ↗ |
| 4 | Altium Growth Fund, LP | 2.86M | 9.99% | — | 2.86M | — | 2.86M | PN | Delaware, United States of America | 2024-02-21 | ↗ |
| 5 | Altium Growth GP, LLC | 2.86M | 9.99% | — | 2.86M | — | 2.86M | OO | Delaware, United States of America | 2024-02-21 | ↗ |
| 6 | Armistice Capital, LLC | 2.13M | 7.60% | — | 2.13M | — | — | IA, OO | Delaware | 2024-02-14 | ↗ |
| 7 | Steven Boyd | 2.13M | 7.60% | — | 2.13M | — | — | HC, IN | United States of America | 2024-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
100.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+100,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-14 | NATAN DAVID | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 100,000 | D | ↗ |
| 2025-01-13 | Roy Michel | Officer | — | — | Common Stock | 0 | 0.00 | — | 1 | D | ↗ |
| 2024-03-04 | Slilaty Steve N. | Director / Officer / 10% Owner | P-Purchase | A | Series B Preferred Stock | 100,000 | 0.10 | 10.0K | 130,000 | — | ↗ |
| 2024-02-08 | Slilaty Steve N. | Director / Officer / 10% Owner | P-Purchase | A | Series B Preferred Stock | 20,000 | 0.10 | 2.0K | 30,000 | — | ↗ |
| 2024-01-26 | Beaudoin Marc | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-11-30 | Sebaaly Camille | Officer | P-Purchase | A | Common Stock | 30,000 | 0.76 | 22.9K | 174,465 | — | ↗ |
| 2022-10-20 | Chamoun Malek | Director | — | D | Common Stock, par value $0.001 per share | 0 | 0.00 | — | 3,700,000 | — | ↗ |
| 2022-06-03 | Sebaaly Camille | Officer | P-Purchase | A | Common Stock | 25,000 | 1.22 | 30.5K | 144,465 | — | ↗ |
| 2022-02-18 | Slilaty Steve N. | Director / Officer | D-Return | D | Series B Preferred Stock | 990,000 | 0.10 | 99.0K | 10,000 | — | ↗ |
| 2022-02-10 | NATAN DAVID | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-10 | Keller Andrew Mark | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-10-31 | TELSEY ANDREW I | Director | — | D | Common Stock | 0 | 0.00 | — | 3,000 | — | ↗ |
| 2021-10-31 | Kish James Daniel | Director | — | D | Common Stock | 0 | 0.00 | — | 287,100 | — | ↗ |
| 2021-10-31 | Kiderchah Rabi | Director | — | D | Common Stock | 0 | 0.00 | — | 325,000 | — | ↗ |
| 2021-01-06 | Slilaty Steve N. | Director / Officer | A-Award | A | Common Stock | 20,000,000 | 0.00 | 20.0K | 23,343,461 | — | ↗ |
| 2021-01-06 | Sebaaly Camille | Director / Officer | A-Award | A | Common Stock | 20,000,000 | 0.00 | 20.0K | 23,893,086 | — | ↗ |
| 2021-01-06 | MERZOUKI ABDERRAZZAK | Director / Officer | A-Award | A | Common Stock | 20,000,000 | 0.00 | 20.0K | 23,342,500 | — | ↗ |
| 2020-06-17 | Slilaty Steve N. | Director / Officer | A-Award | A | Series "B" Preferred Stock | 500,000 | 0.10 | 50.0K | 1,000,000 | — | ↗ |
| 2019-12-31 | Slilaty Steve N. | Director / Officer | J-Other | A | Common Stock | 323,673 | 0.00 | 323.67 | 861,209 | — | ↗ |
| 2019-12-31 | Sebaaly Camille | Director / Officer | A-Award | D | Common Stock | 323,673 | 0.00 | 323.67 | 0 | — | ↗ |
| 2019-12-19 | Slilaty Steve N. | Director / Officer | A-Award | A | Common Stock | 1,300,000 | 0.00 | 1.3K | 3,343,461 | — | ↗ |
| 2019-12-19 | Sebaaly Camille | Director / Officer | A-Award | A | Common Stock | 1,300,000 | 0.00 | 1.3K | 3,893,086 | — | ↗ |
| 2019-12-19 | MERZOUKI ABDERRAZZAK | Director / Officer | A-Award | A | Common Stock | 1,300,000 | 0.00 | 1.3K | 3,342,500 | — | ↗ |
| 2019-10-20 | Slilaty Steve N. | Director / Officer | A-Award | A | Common Stock | 1,100,000 | 0.00 | 1.1K | 2,043,461 | — | ↗ |
| 2019-10-20 | Sebaaly Camille | Director / Officer | A-Award | A | Common Stock | 1,100,000 | 0.00 | 1.1K | 2,593,086 | — | ↗ |
| 2019-10-20 | MERZOUKI ABDERRAZZAK | Director / Officer | A-Award | A | Common Stock | 1,100,000 | 0.00 | 1.1K | 2,042,500 | — | ↗ |
| 2019-09-11 | Sebaaly Camille | Director / Officer | A-Award | A | Common Stock | 550,000 | 0.00 | 550.00 | 1,493,086 | — | ↗ |
| 2019-09-02 | Slilaty Steve N. | Director / Officer / 10% Owner | A-Award | A | Common Stock | 13,000,000 | 0.00 | 13.0K | 18,869,219 | — | ↗ |
| 2019-09-02 | Sebaaly Camille | Director / Officer / 10% Owner | A-Award | A | Common Stock | 13,000,000 | 0.00 | 13.0K | 18,861,719 | — | ↗ |
| 2019-09-02 | MERZOUKI ABDERRAZZAK | Director / Officer | A-Award | A | Common Stock | 13,000,000 | 0.00 | 13.0K | 18,850,000 | — | ↗ |
| 2018-08-27 | Slilaty Steve N. | Director / Officer | A-Award | A | Common Stock | 38,000,000 | 0.00 | 38.0K | 117,384,373 | — | ↗ |
| 2018-08-27 | Sebaaly Camille | Director / Officer | A-Award | A | Common Stock | 38,000,000 | 0.00 | 38.0K | 117,234,373 | — | ↗ |
| 2018-08-27 | MERZOUKI ABDERRAZZAK | Director / Officer | A-Award | A | Common Stock | 38,000,000 | 0.00 | 38.0K | 117,000,000 | — | ↗ |
| 2018-06-20 | Slilaty Steve N. | Director / Officer | A-Award | A | Common Stock | 27,000,000 | 0.00 | 27.0K | 79,384,373 | — | ↗ |
| 2018-06-20 | Sebaaly Camille | Director / Officer | A-Award | A | Common Stock | 27,000,000 | 0.00 | 27.0K | 79,234,373 | — | ↗ |
| 2018-06-20 | MERZOUKI ABDERRAZZAK | Director / Officer | A-Award | A | Common Stock | 27,000,000 | 0.00 | 27.0K | 80,467,000 | — | ↗ |
| 2018-04-22 | MERZOUKI ABDERRAZZAK | Director / Officer | A-Award | A | Common Stock | 12,000,000 | 0.00 | 12.0K | 12,000,000 | — | ↗ |
| 2017-07-20 | Slilaty Steve N. | Director / Officer | A-Award | A | Common Stock | 14,000,000 | 0.00 | 14.0K | 52,384,373 | — | ↗ |
| 2017-07-20 | Sebaaly Camille | Director / Officer | A-Award | A | Common Stock | 14,000,000 | 0.00 | 14.0K | 52,234,373 | — | ↗ |
| 2017-07-20 | MERZOUKI ABDERRAZZAK | Director / Officer | A-Award | A | Common Stock | 14,000,000 | 0.00 | 14.0K | 53,467,000 | — | ↗ |
| 2016-12-06 | Slilaty Steve N. | Director / Officer | A-Award | A | Common Stock | 26,000,000 | 0.00 | 26.0K | 38,384,373 | — | ↗ |
| 2016-12-06 | Sebaaly Camille | Director / Officer | A-Award | A | Common Stock | 26,000,000 | 0.00 | 26.0K | 38,234,373 | — | ↗ |
| 2016-12-06 | MERZOUKI ABDERRAZZAK | Director / Officer | A-Award | A | Common Stock | 26,000,000 | 0.00 | 26.0K | 39,467,000 | — | ↗ |
| 2016-10-10 | Slilaty Steve N. | Director / Officer / 10% Owner | J-Other | D | Common Stock | 136,861,968 | 0.00 | — | 215,014,224 | — | ↗ |
| 2016-10-10 | Sebaaly Camille | Director / Officer / 10% Owner | J-Other | A | Common Stock | 129,468,927 | 0.00 | — | 129,468,927 | — | ↗ |
| 2016-10-10 | Advanomics Corp | 10% Owner | J-Other | D | Common Stock | 136,861,968 | 0.00 | — | 215,014,224 | — | ↗ |
| 2016-07-08 | Slilaty Steve N. | Director / Officer / 10% Owner | J-Other | A | Common Stock | 321,305,416 | 0.00 | 835.4K | 351,876,192 | — | ↗ |
| 2016-07-08 | Advanomics Corp | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 351,876,192 | — | ↗ |
| 2016-04-22 | Slilaty Steve N. | Director / Officer | A-Award | A | Common Stock | 12,000,000 | 0.01 | 84.0K | 12,384,373 | — | ↗ |
| 2016-04-22 | Sebaaly Camille | Director / Officer | A-Award | A | Common Stock | 12,000,000 | 0.01 | 84.0K | 12,234,373 | — | ↗ |
| 2016-04-22 | MERZOUKI ABDERRAZZAK | Director / Officer | A-Award | A | Common Stock | 12,000,000 | 0.01 | 84.0K | 13,467,000 | — | ↗ |
| 2016-04-12 | Slilaty Steve N. | Director / Officer | P-Purchase | A | Common Stock | 253,082 | 0.20 | 50.0K | 30,570,776 | — | ↗ |
| 2015-05-27 | Slilaty Steve N. | Director / Officer / 10% Owner | P-Purchase | A | Series "B" Preferred Stock | 500,000 | 0.10 | 50.0K | 500,000 | — | ↗ |
| 2015-02-20 | MERZOUKI ABDERRAZZAK | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 877,000 | — | ↗ |
| 2015-02-20 | Di Turi Michele | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-01-09 | Slilaty Steve N. | Director / Officer / 10% Owner | J-Other | A | Common Stock | 150,000 | 0.02 | 3.0K | 384,373 | — | ↗ |
| 2012-09-04 | Slilaty Steve N. | Director / Officer / 10% Owner | J-Other | D | Common Stock | 2,591,500 | 0.05 | 129.6K | 31,517,694 | — | ↗ |
| 2011-12-21 | Slilaty Steve N. | Director / Officer / 10% Owner | C-Conversion | A | Common Stock | 17,000,000 | 0.00 | — | 34,109,194 | — | ↗ |
| 2009-10-15 | Slilaty Steve N. | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 234,373 | — | ↗ |
| 2009-10-15 | Sebaaly Camille | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 234,373 | — | ↗ |
| 2009-10-15 | Di Turi Michele | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 234,373 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-86.1K
Shares Outstanding
5.01M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Mr. Camille Sebaaly Chief Financial Officer | 315.0K | 380.0K | — | — | — | — | 695.0K | 0.00% | ↗ |
| 2 | 2023 | Dr. Steve N. Slilaty Chief Executive Officer and Director | 378.0K | 182.0K | — | — | — | — | 560.0K | 0.00% | ↗ |
| 3 | 2023 | Dr. Abderrazzak Merzouki Chief Operating Officer and Director | 252.0K | 8.0K | — | — | — | — | 260.0K | 0.00% | ↗ |
| 4 | 2022 | Camille Sebaaly Chief Financial Officer | 300.0K | 630.0K | — | — | — | — | 930.0K | 0.00% | ↗ |
| 5 | 2022 | Mr. Camille Sebaaly Chief Financial Officer | 300.0K | 630.0K | — | — | — | — | 930.0K | 0.00% | ↗ |
| 6 | 2022 | Dr. Abderrazzak Merzouki Chief Operating Officer and Director | 240.0K | 245.0K | — | — | — | — | 485.0K | 0.00% | ↗ |
| 7 | 2022 | Dr. Steve N. Slilaty Chief Executive Officer and Director | 360.0K | 10.0K | — | — | — | — | 370.0K | 0.00% | ↗ |
| 8 | 2021 | Dr. Steve N. Slilaty Chief Executive Officer and Director | 156.4K | — | 306.0K | — | — | — | 462.4K | 66.18% | ↗ |
| 9 | 2021 | Dr. Abderrazzak Merzouki Chief Operating Officer and Director | 109.9K | — | 306.0K | — | — | — | 415.9K | 73.57% | ↗ |
| 10 | 2021 | Camille Sebaaly Chief Financial Officer | 40.0K | — | 306.0K | — | — | — | 346.0K | 88.44% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Steve N. Slilaty | Chairman, President & Chief Executive Officer | 546.0K | — |
| Camille Sebaaly | CFO, Secretary & Director | 412.3K | male |
| Michel Roy | Chief Commercial Officer | 283.2K | male |
| Malek Chamoun | Chief Development Officer | — | male |
| Robert G. Ferreira | President of Sunshine Bio Investments Inc | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2022-06-30 | 2024-06-12 | Roger Williams | TX25 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SBFM
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
